Objective: Sporadic late-onset nemaline myopathy (SLONM) is a rare, late-onset myopathy that progresses subacutely. If associated with a monoclonal gammopathy of unknown significance (MGUS), the outcome is unfavorable: the majority of these patients die within 1 to 5 years of respiratory failure. This study aims to qualitatively assess the long-term treatment effect of high-dose melphalan (HDM) followed by autologous stem cell transplantation (SCT) in a series of 8 patients with SLONM-MGUS.
Sporadic late-onset nemaline myopathy (SLONM) is a rare, late-onset myopathy that progresses subacutely. Limb-girdle and axial weakness and atrophy predominate the clinical picture. Distal weakness, head drop, respiratory insufficiency, and dysphagia can also occur. 1, 2 Patients may be suspected to have motor neuron disease because of the rapid course and severe atrophy. Recognition of nemaline rods on trichrome and a-actinin staining or electron microscopy is crucial.
SLONM is in a significant proportion of cases associated with a monoclonal gammopathy of unknown significance (MGUS), a combination that portends an unfavorable outcome: the majority of these patients die within 1 to 5 years of respiratory failure. 3 In 2008, our 2 groups concurrently but independently reported the effective treatment of 2 patients with SLONM associated with MGUS (SLONM-MGUS) with high-dose melphalan (HDM) followed by autologous stem cell transplantation (SCT). Both patients showed significant increase of muscle strength and functional improvement up to independent walking and even running in one. 4, 5 The editorial rightly commented that the duration of follow-up (15-24 months) was short, and suggested the possible effectiveness of alternative, safer therapies, such as thalidomide or lenalidomide. 6 Since then, only 4 other SLONM-MGUS patients have been reported in the literature, with similar treatment responses on HDM-SCT in 2 of them. [7] [8] [9] This retrospective case series aims to assess the long-term treatment response of HDM followed by autologous SCT (HDM-SCT) in 8 patients with SLONM-MGUS.
METHODS Methods of clinical, hematologic, and histopathologic data collection, definitions of clinical and hematologic treatment response, and information on patient consents are listed in appendix e-1 on the Neurology ® Web site at Neurology.org.
RESULTS
The clinical response to treatment varied from long-lasting moderate to good for 7 patients (I: patients 1 [second HDM-SCT], 2, 3, 4, 6 [second HDM-SCT], 7, and 8), to temporarily moderategood in 2 patients who subsequently received a second HDM-SCT (II: patients 1 and 6), and no response (IV: patient 5). In parallel, the hematologic responses diverged from complete response (patients 1 [first HDM-SCT], 2, 4, 6 [first HDM-SCT], 7, and 8), very good partial response (patients 1 [second HDM-SCT] and 3), partial response (patient 6 [second HDM-SCT]), to progressive disease (patient 5). This latter patient showed neither a clinical nor a hematologic response and died. For patient 6, the period after the second HDM-SCT was particularly difficult because of a severe aspiration pneumonia, requiring intensive care management including tracheostomy and gastrostomy, but a significant improvement gradually started after 3 months. Patient 8 was in very poor shape with significant weight loss and swallowing problems when she entered the hospital for SCT. She developed bilateral aspiration pneumonia and had to be intubated, requiring the HDM-SCT to be postponed. Table 1 presents the  main features of the myopathy, and table 2 shows the responses to treatment. The individual case histories of the 8 patients are added as appendix e-2 ( figure) .
The only completely unresponsive patient (patient 5) differed from the other patients for the following characteristics: a particularly long duration before the autologous HDM-SCT (11 years) and no hematologic response after HDM. In the 2 patients with only a temporary response to treatment (patients 1 and 6), the delay before the graft was variable: 2 and 5 years, respectively. In the first patient, muscle weakness recurred in parallel with a reappearance of M protein, although at a much lower level than before (0.1 g/L against 7.4 g/L before first graft), probably related to higher awareness and regular measurements. In patient 6, the clinical worsening 2 years after the graft was also associated with a large increase of M protein (17.8 g/L against 9.4 g/L before first graft). Age at onset of muscle weakness, severity of muscle weakness before HDM-SCT, and the level and type of M protein and results of bone marrow aspiration before the graft did not correlate with the clinical response.
Lastly, 4 patients were treated after HDM-SCT with lenalidomide to prevent a hematologic relapse after HDM-SCT or to induce a (unsuccessful) hematologic response in the patient with stable disease after treatment. However, 2 other patients remained in complete response after HDM-SCT without the use of lenalidomide so the value of adding this drug cannot be ascertained. DISCUSSION This case series shows the long-term follow-up of 8 patients with SLONM-MGUS after treatment with HDM-SCT. Seven patients showed a lasting moderate-good clinical response (2 of which only after the second treatment), 6 with a very good partial or complete hematologic response, and one with a partial hematologic response. One patient showed no clinical or hematologic response and died. Factors that may portend an unfavorable clinical outcome are a long disease course before HDM-SCT and a poor hematologic response to treatment. Age at onset, level and type of M protein, and severity of muscle weakness before the graft were not associated with outcome. This underlines the importance of early recognition of this disorder by M protein screening and (repeated) muscle biopsies in clinically suspected cases. Timely diagnosis will also enable start of treatment when the patient is still in a relatively good clinical condition. The limitations of this case series are that it is a retrospective study, the number of patients is limited, and treatment is not blinded. However, it is the first longterm follow-up of a series of SLONM-MGUS patients treated with HDM-SCT and undoubtedly shows the positive treatment response with a follow-up of 9 months to 8 years in this otherwise fatal disease.
SLONM pathophysiologic mechanisms are unknown, but several observations are suggestive of an association between the (level of) the M protein and the disorder 4,5 : appearance of rods later in the course of the disease (which in this series is unlikely to be due to sampling error); responsiveness to antiplasma cell chemotherapy; disappearance of nemaline rods after treatment; increase of the M protein level preceding clinical deterioration; and the absence of a hematologic response to HDM-SCT paralleling the lack of clinical improvement in patient 5. The disease may therefore be classified as an MGUS with a toxic M protein similar to POEMS (polyneuropathy, organomegaly, endocrinopathy/edema, M protein, skin abnormalities) syndrome. Here, not the aggregation and deposition of the monoclonal antibodies in affected tissue but the antibody activity toward autogenous antigens, possibly augmented by other humoral mediators, is considered causative. 10 This and other MGUS with a toxic M protein-like disorder show a similar response after HDM-SCT as observed in this SLONM-MGUS series. This calls for further investigations in the exact role of the M protein in SLONM-MGUS.
Based on this series and the experience in management of other hematologic diseases with dangerous B-cell clones, we suggest that HDM-SCT should be the first-line therapy for SLONM-MGUS: first, the natural course of SLONM-MGUS is fatal; second, the goal of treatment should be to suppress the clone as soon as possible to reduce the monoclonal protein and its toxic effects; third, treatment is preferably started when the patient is still in a relatively good clinical condition. Furthermore, because the severity of SLONM is likely to be correlated to the quantity and/or quality of the toxic M protein after HDM-SCT, consolidation and maintenance therapy may be considered to achieve and maintain an optimal hematologic response.
In short, this retrospective SLONM-MGUS case series on the long-term follow-up shows that the probability of survival, muscle strength, and functional capacities improve after treatment with HDM-SCT (class IV evidence). Factors associated with positive benefit of HDM-SCT in SLONM-MGUS are shorter duration between onset of symptoms and treatment and a good hematologic response to treatment. This again underscores the importance of early recognition of this rare, acquired myopathy.
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